HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.

BACKGROUND:HBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine, adefovir, telbivudine, entecavir, and tenofovir. M...

Full description

Bibliographic Details
Main Authors:	Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5249087?pdf=render

Similar Items

Manifestations of perihepatic lymph nodes in acute flare of chronic hepatitis B: association with HBeAg status and with HBeAg seroconversion.
by: Yen-Ling Ko, et al.
Published: (2015-01-01)

Study of hepatic histomorphology in HBeAg+ and HBeAg− patients with CHB: Experience from Bangladesh
by: Ayub Al Mamun, et al.
Published: (2013-01-01)

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks
by: Xiaomei Wang, et al.
Published: (2020-10-01)

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Treated with Pegylated Interferon α
by: Hu Yao-ren, et al.
Published: (2014-03-01)

HBeAg-negative chronic hepatitis
by: M M Ibragimova, et al.
Published: (2004-02-01)

Develop genetic programming to predict the state of seroconversion of HBeAg
by: Chu-Yu Chin, et al.
Published: (2005)

Correlations of HBV Genotypes, Mutations Affecting HBeAg Expression and HBeAg/ anti-HBe Status in HBV Carriers
Published: (2006-01-01)

Caucasian Ethnicity, but Not Treatment Cessation Is Associated with HBsAg Loss Following Nucleos(t)ide Analogue-Induced HBeAg Seroconversion
by: Stijn Van Hees, et al.
Published: (2019-07-01)

Differential plasma microRNA profiles in HBeAg positive and HBeAg negative children with chronic hepatitis B.
by: Thilde Nordmann Winther, et al.
Published: (2013-01-01)

The Prediction of HBeAg Seroconversion and DNA Sequence Mutation Rate of HBV
by: Wei-Liang Liu, et al.
Published: (2006)

Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients
by: Young Jip Kim, et al.
Published: (2013-09-01)

Relationship of T Cell Immunity and HBeAg Loss During Telbivudine Treatment in Patients with HBeAg-positive Chronic Hepatitis B
by: Yih-Tsong Shiau, et al.
Published: (2014)

Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues.
by: Teresa Broquetas, et al.
Published: (2017-01-01)

Host Factors on Spontaneous HBeAg Seroconversion in Chronic HBV Infected Patients
by: Jia-Feng Wu, et al.
Published: (2010)

Significance of changes in hepatic histology from patients with HBeAg(+) or HBeAg(-) chronic hepatitis B and normal or mildly elevated alanine aminotransferase
by: LAN Lin
Published: (2015-04-01)

Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
by: Byung-Cheol Song, et al.
Published: (2014-12-01)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
by: Cai S, et al.
Published: (2018-04-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Seroconversion of hepatitis B envelope antigen (HBeAg) by entecavir in a child with chronic hepatitis B
by: Mohammed Y Hasosah, et al.
Published: (2012-01-01)

Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis
by: Yun Liu, et al.
Published: (2019-09-01)

Predictors of HBeAg seroconversion after long-term nucleos(t)ide analogues treatment for chronic hepatitis B: a multicenter study in real clinical setting
by: Weiyan Yu, et al.
Published: (2017-05-01)

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog
by: Ji X, et al.
Published: (2020-06-01)

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
by: Yu-Li Zeng, et al.
Published: (2021-02-01)

Lamivudine therapy in HBeAg negative chronic hepatitis B patients
by: E. Guclu, et al.
Published: (2014-04-01)

Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
by: Gail V Matthews, et al.
Published: (2013-01-01)

Viral Biomarkers in Chronic HBeAg Negative HBV Infection
by: Emilia Hadziyannis, et al.
Published: (2018-09-01)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
by: Hui Ma, et al.
Published: (2016-01-01)

Characterization of HBeAg-negative chronic hepatitis B in western Brazilian Amazonia
by: Flamir da Silva Victoria, et al.

The Immune Modulatory Function of the Hepatitis B Virus e Antigen (HBeAg)
by: Jeng-chiao Kuo, et al.
Published: (2002)

A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment
by: TAO Junxiu, et al.
Published: (2017-08-01)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
by: Yang Zhang, et al.
Published: (2019-01-01)

Study on Post-Treatment Relapse in HBeAg Positive CHB Patients.
by: Junfeng Lu, et al.
Published: (2015-01-01)

Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
by: Florian vanBömmel, et al.
Published: (2021-10-01)

Influence of quantitative changes in HBeAg on the therapeutic efficacy of antiviral drugs
by: XIE Zhiwei
Published: (2013-02-01)

HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection
by: Sara Ferrando-Martinez, et al.
Published: (2019-09-01)

The Effects of HBcAg and HBeAg on the Expression of Cytokine Genes from Murine Macrophages
by: Kung-yen Chang, et al.
Published: (1999)

Coffee consumption and hepatocellular carcinoma in patients with HBeAg negative chronic hepatitis B
by: Chien-Lin Chen, et al.
Published: (2020-03-01)

Clinical efficacy of entecavir in HBeAg-negative chronic hepatitis B with compensated cirrhosis
by: HAN Benli
Published: (2016-08-01)

Cost-effectiveness of entecavir treatment in patients with HBeAg-negative chronic hepatitis B
by: Yu-Wen Tsai, et al.
Published: (2009)

Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients
by: Dimitri Loureiro, et al.
Published: (2019-01-01)

Cannot write session to /tmp/vufind_sessions/sess_thv5r7t523k96nfaqrotatd56u